Terms: = Leukemia AND MAPK1, MAPK2, 5594, ENSG00000100030, P28482, ERK2, p40, PRKM1, p38, p41, ERT1, p41mapk, PRKM2, P42MAPK, ERK AND Prognosis
132 results:
1. LSP1 promotes the progression of acute myelogenous leukemia by regulating KSR/erk signaling pathway and cell migration.
Li T; Gui X; Li B; Hu X; Wang Y
Hematology; 2024 Dec; 29(1):2330285. PubMed ID: 38511641
[TBL] [Abstract] [Full Text] [Related]
2. Discovery of FLT3-targeting PROTACs with potent antiproliferative activity against acute myeloid leukemia cells harboring FLT3 mutations.
Wang Z; Lu X; Liu C; Huang F; Lu T; Chen Y; Liu L; Lu S
Eur J Med Chem; 2024 Mar; 268():116237. PubMed ID: 38387337
[TBL] [Abstract] [Full Text] [Related]
3. A pan-cancer analysis of the MAPK family gene and their association with prognosis, tumor microenvironment, and therapeutic targets.
Qin YY; Yang Y; Ren YH; Gao F; Wang MJ; Li G; Liu YX; Fan L
Medicine (Baltimore); 2023 Nov; 102(45):e35829. PubMed ID: 37960824
[TBL] [Abstract] [Full Text] [Related]
4. A gain-of-function p53 mutant synergizes with oncogenic NRAS to promote acute myeloid leukemia in mice.
Rajagopalan A; Feng Y; Gayatri MB; Ranheim EA; Klungness T; Matson DR; Lee MH; Jung MM; Zhou Y; Gao X; Nadiminti KV; Yang DT; Tran VL; Padron E; Miyamoto S; Bresnick EH; Zhang J
J Clin Invest; 2023 Dec; 133(24):. PubMed ID: 37847561
[TBL] [Abstract] [Full Text] [Related]
5. Simvastatin Preferentially Targets FLT3/ITD Acute Myeloid leukemia by Inhibiting MEK/erk and p38-MAPK Signaling Pathways.
Li G; Yao J; Lu Z; Yu L; Chen Q; Ding L; Fang Z; Li Y; Xu B
Drugs R D; 2023 Dec; 23(4):439-451. PubMed ID: 37847357
[TBL] [Abstract] [Full Text] [Related]
6. FBXO21 mediated degradation of p85α regulates proliferation and survival of acute myeloid leukemia.
Dobish KK; Wittorf KJ; Swenson SA; Bean DC; Gavile CM; Woods NT; Ghosal G; Hyde RK; Buckley SM
Leukemia; 2023 Nov; 37(11):2197-2208. PubMed ID: 37689825
[TBL] [Abstract] [Full Text] [Related]
7. Exosomal circRNA-001264 promotes AML immunosuppression through induction of M2-like macrophages and PD-L1 overexpression.
Du A; Yang Q; Sun X; Zhao Q
Int Immunopharmacol; 2023 Nov; 124(Pt A):110868. PubMed ID: 37657244
[TBL] [Abstract] [Full Text] [Related]
8. Knockdown of neurotrophin receptor-interacting melanoma-associated antigen homolog inhibits acute myeloid leukemia cell growth via the erk pathway.
Zhang H; Wu G; Chen B
Chin J Physiol; 2023; 66(4):276-283. PubMed ID: 37635487
[TBL] [Abstract] [Full Text] [Related]
9. [Research Progress of m6A Demethylase FTO and Its Inhibitors in Acute Myeloid leukemia --Review].
Fang ZH; Zheng SY; Feng WY
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2023 Jun; 31(3):902-906. PubMed ID: 37356958
[TBL] [Abstract] [Full Text] [Related]
10. RAB27B controls palmitoylation-dependent NRAS trafficking and signaling in myeloid leukemia.
Ren JG; Xing B; Lv K; O'Keefe RA; Wu M; Wang R; Bauer KM; Ghazaryan A; Burslem GM; Zhang J; O'Connell RM; Pillai V; Hexner EO; Philips MR; Tong W
J Clin Invest; 2023 Jun; 133(12):. PubMed ID: 37317963
[TBL] [Abstract] [Full Text] [Related]
11. Identification of signature genes and drug candidates for primary plasma cell leukemia: An integrated system biology approach.
Chaudhary RK; Patil P; Ananthesh L; Gowdru Srinivasa M; Mateti UV; Shetty V; Khanal P
Comput Biol Med; 2023 Aug; 162():107090. PubMed ID: 37295388
[TBL] [Abstract] [Full Text] [Related]
12. Dual targeting of aberrant DNA and histone methylation synergistically suppresses tumor cell growth in ATL.
Kurahashi Y; Watanabe T; Yamamoto Y; Ureshino H; Kamachi K; Yoshida-Sakai N; Fukuda-Kurahashi Y; Yamashita S; Hattori N; Nakamura H; Kawaguchi A; Ushijima T; Sueoka E; Kimura S
Blood Adv; 2023 Apr; 7(8):1545-1559. PubMed ID: 36516085
[TBL] [Abstract] [Full Text] [Related]
13. FUBP3 regulates chronic myeloid leukaemia progression through PRC2 complex regulated PAK1-erk signalling.
Sharma M; Anandram S; Ross C; Srivastava S
J Cell Mol Med; 2023 Jan; 27(1):15-29. PubMed ID: 36478132
[TBL] [Abstract] [Full Text] [Related]
14. Targeting PI4KA sensitizes refractory leukemia to chemotherapy by modulating the erk/AMPK/OXPHOS axis.
Jiang X; Huang X; Zheng G; Jia G; Li Z; Ding X; Lei L; Yuan L; Xu S; Gao N
Theranostics; 2022; 12(16):6972-6988. PubMed ID: 36276647
[No Abstract] [Full Text] [Related]
15. MYH9 Facilitates Cell Invasion and Radioresistance in Head and Neck Cancer via Modulation of Cellular ROS Levels by Activating the MAPK-Nrf2-GCLC Pathway.
You GR; Chang JT; Li YL; Huang CW; Tsai YL; Fan KH; Kang CJ; Huang SF; Chang PH; Cheng AJ
Cells; 2022 Sep; 11(18):. PubMed ID: 36139430
[TBL] [Abstract] [Full Text] [Related]
16. DNA damage accumulation and repair defects in FLT3-ITD acute myeloid leukemia: Implications for clonal evolution and disease progression.
Lagunas-Rangel FA
Hematol Oncol; 2023 Feb; 41(1):26-38. PubMed ID: 36131612
[TBL] [Abstract] [Full Text] [Related]
17. Chenodeoxycholic acid suppresses AML progression through promoting lipid peroxidation via ROS/p38 MAPK/DGAT1 pathway and inhibiting M2 macrophage polarization.
Liu J; Wei Y; Jia W; Can C; Wang R; Yang X; Gu C; Liu F; Ji C; Ma D
Redox Biol; 2022 Oct; 56():102452. PubMed ID: 36084349
[TBL] [Abstract] [Full Text] [Related]
18. Inhibition of Mcl-1 Synergistically Enhances the Antileukemic Activity of Gilteritinib and MRX-2843 in Preclinical Models of
Wu S; Edwards H; Wang D; Liu S; Qiao X; Carter J; Wang Y; Taub JW; Wang G; Ge Y
Cells; 2022 Sep; 11(17):. PubMed ID: 36078163
[No Abstract] [Full Text] [Related]
19. Netrin-1 induces the anti-apoptotic and pro-survival effects of B-ALL cells through the Unc5b-MAPK axis.
Huang L; An X; Zhu Y; Zhang K; Xiao L; Yao X; Zeng X; Liang S; Yu J
Cell Commun Signal; 2022 Aug; 20(1):122. PubMed ID: 35974411
[TBL] [Abstract] [Full Text] [Related]
20. SPAG1 promotes the development of AML by activating the erk/MAPK signaling pathway and affects the chemotherapy sensitivity of venetoclax.
Liu L; Liu J; Liu XJ; Liu MH; Feng XF; Yang L; Luo JM
Neoplasma; 2022 Sep; 69(5):1108-1118. PubMed ID: 35951456
[TBL] [Abstract] [Full Text] [Related]
[Next]
